The current standard of care for patients with early breast cancer is radiation therapy (RT) after breast conserving surgery to improve cancer control. However, breast cancer is a complex disease, and the benefit of radiation therapy in individual patients varies. Therefore, delivery of radiation therapy in all patients may lead to over-treatment of some of them, potentially resulting in unnecessary treatment toxicity, financial costs and logistical challenges for these patients. However, clinical trials have not consistently identified patients who may safely omit radiation using conventional clinical and pathological characteristics.
EXPERT is an investigator initiated clinical trial which presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.
The primary aim of the trial is to see whether a genomic test of breast cancer tissue can be used to identify women who can safely avoid radiation therapy after breast cancer surgery. The need for radiation therapy after breast cancer surgery depends on the risk of the cancer coming back. If the doctor could identify women who have a very small risk of the cancer coming back, these women may not need radiation therapy and could avoid its side effects.
Breast International Group (BIG); International Breast Cancer Study Group (IBCSG); TROG Cancer Research
Expected Date of Accrual
Prof Boon Chua, Nelune Comprehensive Cancer Centre, NSW, Aust.
Clinical Trial Registration
The journey to becoming the 200th participant for the
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292